Harmony Biosciences (HRMY) Misses Q1 EPS by 21c ; Offers Guidance

Harmony Biosciences (NASDAQ: HRMY) reported Q1 EPS of $0.55, $0.21 worse than the analyst estimate of $0.76. Revenue for the quarter came in at $215.39 million versus the consensus estimate of $228.41 million.

GUIDANCE:

Harmony Biosciences sees FY2026 revenue of $1-1.04 billion, versus the consensus of $1.02 billion.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Bank First National Corp. (BFC) appoints three new directors to board
• BofA lists top 5 themes driving next $1tn in incremental semi sales